We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Micropshere Agent Used with Echocardiography Provides Results Comparable to SPECT

By MedImaging International staff writers
Posted on 25 Feb 2009
A new study concluded that a new microsphere contrast agent used in echocardiography is well tolerated, and that its diagnostic performance in chest pain patients is comparable with single photon emission computed tomography (SPECT) perfusion imaging.

Acusphere, Inc. (Watertown, MA, USA) reported that the study summarized the phase III clinical trial results for Imagify (perflubutane polymer microspheres) for injectable suspension, a cardiovascular drug for the detection of coronary artery disease, the leading cause of death in the United States.

The study was led by Dr. Roxy Senior, consultant cardiologist and director of cardiac research, department of cardiovascular medicine and Institute of Postgraduate Medical Education and Research at Northwick Park Hospital (Harrow, Middlesex, UK), among others. Dr. Senior was the lead clinical investigator for Acusphere's clinical trials for Imagify.

Acusphere is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary microsphere technology. The company's lead product candidate, Imagify, is a cardiovascular drug for the detection of coronary artery disease, the leading cause of death in the United States, for which a New Drug Application (NDA) was submitted to the U.S. Food & Drug Administration (FDA) in April 2008 and filed in June 2008. Imagify is designed to enable ultrasound to compete more effectively with nuclear stress testing, the leading procedure for detecting coronary artery disease.

It is estimated that more than 10 million procedures are done each year in the United States to detect coronary artery disease. Imagify and the company's other product candidates were created using proprietary technology that enables Acusphere to control the porosity and size of nanoparticles and microspheres in a versatile manner that allows them to be customized to address the delivery needs of a variety of drugs.

The study was published in the January 2009 issue of the European Journal of Echocardiography.

Related Links:

Acusphere
Northwick Park Hospital


Medical Radiographic X-Ray Machine
TR30N HF
Ultrasound Needle Guidance System
SonoSite L25
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Half Apron
Demi

Channels

Nuclear Medicine

view channel
Image: CXCR4-targeted PET imaging reveals hidden inflammatory activity (Diekmann, J. et al., J Nucl Med (2025). DOI: 10.2967/jnumed.125.270807)

PET Imaging of Inflammation Predicts Recovery and Guides Therapy After Heart Attack

Acute myocardial infarction can trigger lasting heart damage, yet clinicians still lack reliable tools to identify which patients will regain function and which may develop heart failure.... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.